Dacarbazine: Clinical Trials

119 trials of Dacarbazine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

61 completed, 15 recruiting, 15 unknown, 14 active not recruiting. 119 Phase 2, 16 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2119Completed 61, Recruiting 15, Unknown 15, Active not recruiting 14, Terminated 14
Phase 116Completed 9, Terminated 3, Active not recruiting 2, Unknown 2
Phase 34Recruiting 2, Active not recruiting 1, Terminated 1

Follow Dacarbazine: new trials by email Literature Review of Dacarbazine trials Research Report on Dacarbazine

Trials (filtered) newest first · largest first

All 119 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma
Phase 2RecruitingCity of Hope Medical Center232027-01-012026-11-12
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV
Phase 2RecruitingSun Yat-sen University282026-10-012026-09-29
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma
Phase 2RecruitingM.D. Anderson Cancer Center152026-08-192026-08-31
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
Sintilimab, Dacarbazine or Temozolomide, Cisplatin - Mucosal Melanoma, PD-L1 Positive
Phase 2RecruitingThe First Hospital of Jilin University2202026-04-102026-09-03
A Phase II Trial of LM103 in Advanced Melanoma
LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin - Advanced Melanoma
Phase 2RecruitingSuzhou BlueHorse Therapeutics Co., Ltd.922025-12-162026-08-31
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Doxorubicin, Ifosfamide, Dacarbazine - Sarcoma,Soft Tissue
Phase 2RecruitingSwiss Cancer Institute242025-10-272025-12-30
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV
Phase 2 / Phase 3RecruitingLinnaeus Therapeutics, Inc.1352025-08-062026-04-22
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma
Brentuximab Vedotin, Etoposide, Cyclophosphamide - Hodgkin Lymphoma, Advanced Hodgkin Lymphoma
Phase 2RecruitingUniversity of Miami482025-07-152026-11-18
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Nivolumab, Doxorubicin, Vinblastine - Hodgkin Lymphoma, Adult
Phase 2RecruitingNational Medical Research Radiological Centre of the Ministry of Health of Russia542025-04-152025-11-26
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Biospecimen Collection, Computed Tomography, Dacarbazine - Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Phase 2RecruitingUniversity of Washington1252025-03-062026-09-09
A Study of GC101 TIL in Advanced Melanoma
GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin - Melanoma
Phase 2RecruitingShanghai Juncell Therapeutics982024-12-202026-08-05
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child
Phase 2 / Phase 3RecruitingChildren's Cancer Group, China962024-09-252026-03-19
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma
Phase 2RecruitingMemorial Sloan Kettering Cancer Center712024-04-172026-04-23
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
Biopsy, Biospecimen Collection, Computed Tomography - Classic Hodgkin Lymphoma
Phase 2Active not recruitingNorthwestern University302024-02-062026-07-13
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab - Hodgkin Lymphoma
Phase 2Active not recruitingM.D. Anderson Cancer Center252023-12-142026-10-06
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma
Phase 2 / Phase 3Active not recruitingIDEAYA Biosciences4202023-10-312026-02-17
Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma
Doxorubicin, dacarbazine - Leiomyosarcoma, Uterine Leiomyosarcoma
Phase 2RecruitingBlokhin's Russian Cancer Research Center1002023-01-242026-11-17
PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma
Tislelizumab Injection - Advanced Melanoma
Phase 2UnknownHenan Cancer Hospital402022-12-302023-10-24
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Brentuximab vedotin, Rituximab, Doxorubicin - Hodgkin Lymphoma
Phase 2UnknownBeijing Children's Hospital442022-10-012024-01-12
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma
Phase 2Active not recruitingUniversity of Virginia242022-07-262026-05-14

Showing 20 of 119. Sign in to see all of them.

Conditions studied

Melanoma (44)  ·  Hodgkin Disease (32)  ·  Lymphoma (10)  ·  Sarcoma (9)  ·  Neoplasm Metastasis (6)  ·  Uveal Melanoma (6)  ·  Leiomyosarcoma (5)  ·  Neoplasms (4)  ·  HIV Infections (3)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (2)  ·  Sarcoma, Synovial (2)  ·  Skin Neoplasms (2)  ·  Solitary Fibrous Tumors (2)  ·  AIDS-Related Complex (1)  ·  Acquired Immunodeficiency Syndrome (1)

Sponsors

M.D. Anderson Cancer Center (6)  ·  National Cancer Institute (NCI) (4)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Merck Sharp & Dohme LLC (3)  ·  Northwestern University (3)  ·  Philogen S.p.A. (3)  ·  Bayer (2)  ·  Bristol-Myers Squibb (2)  ·  City of Hope Medical Center (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Henan Cancer Hospital (2)  ·  Massachusetts General Hospital (2)  ·  Radiation Therapy Oncology Group (2)  ·  Seagen Inc. (2)

Countries

United States (71)  ·  Germany (22)  ·  Italy (19)  ·  Spain (15)  ·  Canada (14)  ·  France (14)  ·  United Kingdom (14)  ·  China (12)  ·  Netherlands (12)  ·  Switzerland (11)  ·  Australia (9)  ·  Belgium (9)  ·  Poland (8)  ·  Brazil (5)  ·  Russia (5)

Top investigators

Adil Daud, M.D. (2)  ·  Anas Younes, MD (2)  ·  Claus Garbe, Prof. M.D. (2)  ·  Agop Y. Bedikian, MD (1)  ·  Alba Rubio (1)  ·  Albrecht Reichle, Professor (1)  ·  Aleksei V. Novik, MD, PhD (1)  ·  Alex F Herrera (1)  ·  Alison Moskowitz, MD (1)  ·  Anatolij D Namgaladze, Master (1)

Results publications

PMID 40135712, PMID 37505794, PMID 11904735, PMID 16051328, PMID 16170182, PMID 16446334, PMID 16826357, PMID 17023156, PMID 17443000, PMID 18445842, PMID 20564083, PMID 20572040, PMID 21079154, PMID 21750549, PMID 22028492, PMID 22371887, PMID 23077008, PMID 23735514, PMID 24359243, PMID 24930625, PMID 24938562, PMID 25086465, PMID 26377597, PMID 26407818, PMID 27451390, PMID 27465021, PMID 27596353, PMID 27921276, PMID 28327988, PMID 28439879, PMID 28961465, PMID 29038340, PMID 29177094, PMID 29280762, PMID 29394125, PMID 29584546, PMID 29681762, PMID 30049811, PMID 30179569, PMID 30202085, PMID 30723079, PMID 30736858, PMID 31112476, PMID 31186274, PMID 31331918, PMID 31371315, PMID 31395089, PMID 31401903, PMID 32305010, PMID 32352505

NIH funding

2004 (2), 2014 (2), 2023 (2), P30CA060553 (2), U10CA180821 (2), 2005 (1), 2008 (1), 2009 (1), 2015 (1), 2017 (1), M01RR000096 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1)